La catena delle opzioni mostra i dati chiave delle opzioni azionarie di DBV Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per DBV Technologies..

DBV Technologies (NASDAQ:DBVT) Azioni, Catena delle Opzioni

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV Announces Positive Regulatory Updates for the Viaskin&#xAE; Peanut Patch in the United States and Europe
<ul>
<li>DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old&nbsp;</li>
<li>BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025</li>
<li>VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025&nbsp;&nbsp;</li>
<li>European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe</li>
<li>Company to host investor conference call at 5:00pm ET today &nbsp;</li>
</ul>
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe. DBV intends to formalize the Accelerated Approval guidance provided by the FDA via submission of a meeting request.

Biotech

News

Global

General

DBVT

DBV Announces Regulatory Updates For The Viaskin Peanut Patch In The U.S. And Europe; BLA Submission Under Accelerated Approval Is Subject To Completion Of A 6-Month Supplemental Safety Study In Toddlers To Be Initiated In Q2 2025; VITESSE Phase 3 Study Evaluating The Viaskin Peanut Patch In Children Ages 4 – 7 Years-old Exceeded Enrollment Goals

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $5 Price Target

DBV Technologies Completes Screening For VITESSE Phase 3 Trial Evaluating Viaskin Peanut Patch In Children Ages 4-7; Topline Results Expected By Q4 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $5 Price Target

JMP Securities analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $4 to $5.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $5

The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved. The Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due to any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.
If the Company is not successful in its financing objectives, the Company could have to scale back its operations, notably by delaying or reducing the scope of its research and development efforts or obtain financing through arrangements with collaborators or others that may require the Company to relinquish rights to its product candidates that the Company might otherwise seek to develop or commercialize independently.
This interim condensed financial information does not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company was unable to continue as a going concern.

DBV Technologies Faces Uncertainties In Securing Necessary Financing Under Favorable Terms Due To Potential Global Financial Disruptions, With Risks Exacerbated By Economic Downturns, Potentially Forcing Operational Scale-Backs Or Unwanted Collaborative Financial Arrangements, Without Adjustments Made In This Financial Statement For Going Concern Uncertainties

WIIM

DBV Technologies shares are trading lower after the company reported mixed Q2 financial results. The company said there is substantial doubt regarding its ability to continue as a going concern.

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 30.77 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $1.16 million which missed the analyst consensus estimate of $1.68 million by 30.89 percent. This is a 49.52 percent decrease over sales of $2.30 million the same period last year.

Earnings

DBV Technologies Q2 EPS $(0.34) Beats $(0.45) Estimate, Sales $1.16M Miss $1.68M Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares moved upwards by 124.3% to $0.98 during Thursday's pre-market session. The company's market cap stands at $4.9 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock increased by 116.82% to $2.32. The company's market cap stands at $5.4 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares increased by 36.65% to $0.44. The market value of their outstanding shares is at $4.3 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares moved upwards by 28.26% to $0.37. The company's market cap stands at $4.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 27.08% to $1.15. The market value of their outstanding shares is at $17.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock increased by 24.99% to $2.0. The market value of their outstanding shares is at $47.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares decreased by 18.3% to $0.49 during Thursday's pre-market session. The company's market cap stands at $12.1 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock fell 15.93% to $0.39. The market value of their outstanding shares is at $30.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares fell 14.98% to $0.12. The company's market cap stands at $1.2 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock fell 13.28% to $0.98. The market value of their outstanding shares is at $42.5 million. </li>
<li>Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) shares fell 9.98% to $112.19. The company's market cap stands at $5.9 billion. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 8.61% to $0.53. The market value of their outstanding shares is at $101.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEMD

CERO

FRES

ISPC

MASI

NDRA

ONMD

RNLX

SXTP

VRAX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (&quot;ADSs&quot;) to its ordinary shares (the &quot;ADS Ratio&quot;), nominal value &euro;0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the &quot;ADS Ratio Change&quot;) to be effective on or about June 3rd, 2024. The Company now anticipates that the ADS Ratio Change will be effective on or about June 7th, 2024 (the &quot;Effective Date&quot;).

&nbsp;

Stock Split

DBV Technologies Announces Plan To Implement ADS Ratio Change From 1 ADS To 1/2 Of A Ordinary Share To 1 ADS To 1 Ordinary Share, Anticipates That The ADS Ratio Change Will Be Effective On Or About June 7th, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on or about June 3rd, 2024 (the "Effective Date").

DBV Technologies Announces Plan To Implement ADS Ratio Change From The Current ADS Ratio Of 1 ADS To 1/2 Of One 1 Ordinary Share To A New ADS Ratio Of One 1 ADS To 1 Ordinary Share

<h3>Gainers</h3>
<ul>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares moved upwards by 15.5% to $0.12. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 13.36% to $0.65. The company's market cap stands at $125.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares declined by 13.6% to $0.92 during Thursday's pre-market session. The company's market cap stands at $46.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares decreased by 12.27% to $3.04. The company's market cap stands at $4.1 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) stock declined by 10.9% to $4.66. The market value of their outstanding shares is at $235.3 million. </li>
<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock decreased by 10.12% to $10.22. The company's market cap stands at $12.6 million. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) stock decreased by 9.29% to $0.38. The market value of their outstanding shares is at $13.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares declined by 8.55% to $2.14. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DYNT

EYEN

GLUE

LSDI

NEXI

OTRK

PIRS

SINT

SSKN

WORX

HC Wainwright &amp; Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and lowers the price target from $10 to $5.

HC Wainwright & Co. Maintains Buy on DBV Technologies, Lowers Price Target to $5

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $(0.21) by 233.33 percent. This is a 227.27 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $1.40 million which missed the analyst consensus estimate of $2.27 million by 38.33 percent. This is a 36.36 percent decrease over sales of $2.20 million the same period last year.

Earnings Beats

Earnings Misses

DBV Technologies Q1 EPS $0.28 Beats $(0.21) Estimate, Sales $1.40M Miss $2.27M Estimate

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 25.09% to $16.0. The company's market cap stands at $449.0 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) stock increased by 24.52% to $0.98. The market value of their outstanding shares is at $203.9 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 12.5% to $0.1 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock fell 11.7% to $4.53. The company's market cap stands at $306.8 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock decreased by 11.06% to $1.93. The market value of their outstanding shares is at $191.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares decreased by 10.92% to $0.68. The market value of their outstanding shares is at $29.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock declined by 9.95% to $0.62. The company's market cap stands at $119.8 million. </li>
<li>Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares decreased by 9.86% to $9.42. The company's market cap stands at $634.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

ALLR

APVO

ARAY

BFLY

CNTX

CTMX

PHAR

SKYE

<h3>Gainers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. The market value of their outstanding shares is at $8.3 million. </li>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares increased by 19.31% to $1.05. The market value of their outstanding shares is at $5.7 million. </li>
<li>2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) shares rose 17.7% to $4.72. The company's market cap stands at $242.1 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 13.92% to $0.9. The company's market cap stands at $173.1 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares increased by 13.2% to $5.66. The market value of their outstanding shares is at $54.3 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock rose 12.53% to $0.56. The company's market cap stands at $18.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares declined by 18.2% to $7.6 during Monday's pre-market session. The market value of their outstanding shares is at $5.7 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock fell 14.6% to $0.41. The market value of their outstanding shares is at $3.9 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares decreased by 14.19% to $2.36. The company's market cap stands at $12.6 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares fell 9.36% to $6.3. The market value of their outstanding shares is at $296.8 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock fell 8.92% to $1.53. The company's market cap stands at $3.7 million. </li>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares decreased by 8.82% to $26.26. The company's market cap stands at $31.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BPTS

ELTX

MBRX

MEDS

MTEM

NBTX

TCBP

TSVT

TTNP

XTLB

12 Health Care Stocks Moving In Monday's Pre-Market Session

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly losses of $(0.060) per share. The company reported quarterly sales of $8.875 million which beat the analyst consensus estimate of $412.000 thousand by 2.05K percent. This is a 758.38 percent increase over sales of $(1.348 million) the same period last year.

DBV Technologies Q4 2023 GAAP EPS $(0.060), Sales $8.875M Beat $412.000K Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CINT

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

HBIO

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that DBV Technologies will report an earnings per share (EPS) of $-0.25. 
DBV Technologies bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.15, which was followed by a 0.99% increase in the share price the next day.
Here's a look at DBV Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.24</td>
<td>-0.13</td>
<td>-0.21</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>-0.13</td>
<td>-0.11</td>
<td>-0.23</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>9.0%</td>
<td>6.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709744465_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of DBV Technologies were trading at $0.8449 as of March 05. Over the last 52-week period, shares are down 50.89%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/DBVT/earnings">To track all earnings releases for DBV Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of DBV Technologies's Earnings

In a report released on July 31, Justine Telliez from Kepler Capital maintained a Buy rating on DBV Technologies (0QAJ – Research Report), with a p...

Kepler Capital  Sticks to Their Buy Rating for DBV Technologies (0QAJ)

Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on DBV Technologies SA – American (DBVT – Research Report) and keeping the pr...

Buy Rating Affirmed for DBV Technologies on Strong VITESSE Trial Progress and FDA Collaboration

In a report released on September 24, Justine Telliez from Kepler Capital maintained a Buy rating on DBV Technologies (0QAJ – Research Report), wit...

Warning: DBVT is at high risk of performing badly

The company states: "DBV Technologies (DBVT) announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DB...

DBV Technologies announces positive regulatory updates for Viaskin peanut patch

16:48 EDT DBV Technologies (DBVT) jumps 80% to $1.26 after Viaskin regulatory update Published first on TheFly – the ultimate source for real-time,...

DBV Technologies jumps 80% to $1.26 after Viaskin regulatory update

Press Releases

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Information regarding the total number of voting rights and  total number of shares of the Company as of July 31, 2024

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Comments

DBV Technologies

DBV Technologies (DBVT) Opzioni

DBV Technologies (NASDAQ:DBVT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO